Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 10, 2017, Pages 1307-1316

  Planchard, David ^a   Smit, Egbert F ^b   Groen, Harry J M ^c   Mazieres, Julien ^d   Besse, Benjamin ^a   Helland, Åslaug ^e   Giannone, Vanessa ^f   D'Amelio, Anthony M ^f   Zhang, Pingkuan ^f   Mookerjee, Bijoyesh ^f   Johnson, Bruce E ^g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f NOVARTIS PHARMA AG   (Switzerland)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGE; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASIA; ASTHENIA; BACKACHE; BODY WEIGHT DISORDER; BRAF GENE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPHONIA; DYSPNEA; ERYTHEMA; EUROPE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LUNG EMBOLISM; MALAISE; MALE; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; NORTH AMERICA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; URINARY TRACT INFECTION; VOMITING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; OXIMES; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SURVIVAL RATE;

EID: 85028972802     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30679-4     Document Type: Article

References (30)

1. Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
2. Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
3. Rosell, R, Carcereny, E, Gervais, R, et al., on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
4. Barlesi, F, Mazieres, J, Merlio, JP, et al., for the Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387 (2016), 1415–1426.
5. Kris, MG, Johnson, BE, Berry, LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
6. Paik, PK, Arcila, ME, Fara, M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29 (2011), 2046–2051.
7. Cardarella, S, Ogino, A, Nishino, M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19 (2013), 4532–4540.
8. Marchetti, A, Felicioni, L, Malatesta, S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29 (2011), 3574–3579.
9. Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
10. Langer, CJ, Gadgeel, SM, Borghaei, H, et al., for the KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17 (2016), 1497–1508.
11. V600E-positive advanced non-small-cell lung cancer: a single arm, multicentre, open-label phase 2 trial. Lancet Oncol 17 (2016), 642–650.
12. V600E-mutant metastatic non-small cell lung cancer: an open label, multicentre phase 2 trial. Lancet Oncol 17 (2016), 984–993.
13. Planchard, D, Besse, B, Kim, TM, et al. Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. Proc Am Soc Clin Oncol, 35(suppl), 2017 abstr 9075.
14. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
15. Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
16. Brookmeyer, R, Crowley, J, A confidence interval for the mean survival time. Biometrics 38 (1982), 29–41.
17. Noeparast, A, Teugels, E, Giron, P, et al. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib. Oncotarget, 2016 published online Aug 26. DOI:10.18632/oncotarget.11635.
18. Maemondo, M, Inoue, A, Kobayashi, K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (2010), 2380–2388.
19. Mok, T, Cheng, Y, Zhou, X, et al. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label phase III trial. Proc Am Soc Clin Oncol, 35(suppl), 2017 abstr LBA9007.
20. Solomon, BJ, Mok, T, Kim, DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
21. Peters, S, Camidge, DR, Shaw, AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017 published online June 6. DOI:10.1056/NEJMoa1704795.
22. Soria, JC, Tan, DS, Chiari, R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389 (2017), 917–929.
23. Venur, VA, Ahluwalia, MS, Targeted therapy in brain metastases: ready for primetime?. Am Soc Clin Oncol Educ Book 35 (2016), e123–e130.
24. V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18 (2017), 863–873.
25. Hellmann, MD, Rizvi, NA, Goldman, JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18 (2017), 31–41.
26. Sabari, JK, Montecalvo, J, Chen, R, et al. PD-L1 expression and response to immunotherapy in patients with MET exon 14-alterated non-small cell lung cancers (NSCLC). Proc Am Soc Clin Oncol, 35(suppl), 2017 abstr 8512.
27. Gainor, JF, Shaw, AT, Sequist, LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22 (2016), 4585–4593.
28. Spagnolo, F, Ghiorzo, P, Orgiano, L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 8 (2015), 157–168.
29. Lin, L, Asthana, S, Chan, E, et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci USA 111 (2014), E748–E757.
30. Sen, B, Peng, S, Tang, X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med, 4, 2012, 136ra70.